B Cells--Tumors clinical trials at UCSF
1 in progress, 1 open to new patients
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
open to eligible people ages 18 years and up
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 2 weeks.
San Francisco, California and other locations